We’ll see this week if the pub­lic mar­kets’ love af­fair with biotech uni­corns is still run­ning hot — or not

Can an­oth­er mR­NA spe­cial­ist cap­ture the at­ten­tion of pub­lic in­vestors and main­tain the sec­tor’s rep for host­ing su­per-sized uni­corn val­u­a­tions? 

We’ll find out lat­er this week as BioN­Tech out of Ger­many steers an of­fer­ing in­tend­ed to gen­er­ate more than $250 mil­lion in cash with a val­u­a­tion of $4.45 bil­lion to its cred­it. They’ve been in busi­ness for the last 11 years, backed by the bil­lion­aire Strüng­mann broth­ers. 

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER